

World Journal of *Clinical Cases*

World J Clin Cases 2023 February 26; 11(6): 1224-1433



OPINION REVIEW

- 1224 Collagen matrix scaffolds: Future perspectives for the management of chronic liver diseases
Martinez-Castillo M, Altamirano-Mendoza I, Zielinski R, Priebe W, Piña-Barba C, Gutierrez-Reyes G

MINIREVIEWS

- 1236 Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease
Martin-Grau M, Monleon D
- 1245 Epidemiology and etiology of chemical ocular injury: A brief review
Akgun Z, Selver OB
- 1252 Review of the prevalence, diagnostics, and containment measures of the current mpox outbreak
Sanyaolu A, Marinkovic A, Okorie C, Prakash S, Haider N, Dixon Y, Izurieta R, Badaru O, Smith S
- 1261 Clinical and pathophysiological understanding of the hepatorenal syndrome: Still wrong or still not exactly right?
Wilde B, Canbay A, Katsounas A
- 1267 Flare of the silent pandemic in the era of the COVID-19 pandemic: Obstacles and opportunities
Rayan RA
- 1275 Implications of metabolic dysfunction associated fatty liver disease in COVID-19
Chakraborty R, Sharma D, Kapoor DU, Dwivedi A, Khabiya R, Sen S

ORIGINAL ARTICLE**Retrospective Study**

- 1287 Hyperglycemia in COVID-19 infection without diabetes mellitus: Association with inflammatory markers
Geetha HS, Singh G, Sekar A, Gogtay M, Singh Y, Abraham GM, Trivedi N

Clinical Trials Study

- 1299 Efficacy of invisible advancement correction for mandibular retraction in adolescents based on Pancherz analysis
Kong L, Liu XQ

Observational Study

- 1310 Survey study of the etiology of non-traumatic altered consciousness in the Emergency Department at Suez Canal University Hospital in Egypt
Moussa BS, Abd Elatiff ZM, Kamal Eldin Elhadary GM

- 1318 Metformin effect on internal carotid artery blood flow assessed by area under the curve of carotid artery Doppler in women with polycystic ovarian syndrome

Akram W, Nori W, Abdul Ghani Zghair M

- 1330 Effect of continuous nursing combined with respiratory exercise nursing on pulmonary function of postoperative patients with lung cancer

Qiu QX, Li WJ, Ma XM, Feng XH

CASE REPORT

- 1341 Functioning gonadotroph adenoma with hyperestrogenemia and ovarian hyperstimulation in a reproductive-aged woman: A case report and review of literature

He Y, Gao YT, Sun L

- 1349 Clinical manifestations of adult hereditary spherocytosis with novel *SPTB* gene mutations and hyperjaundice: A case report

Jiang N, Mao WY, Peng BX, Yang TY, Mao XR

- 1356 Post-traumatic cauda equina nerve calcification: A case report

Liu YD, Deng Q, Li JJ, Yang HY, Han XF, Zhang KD, Peng RD, Xiang QQ

- 1365 Endometriosis-associated endometrioid adenocarcinoma of the fallopian tube synchronized with endometrial adenocarcinoma: A case report

Feng JY, Jiang QP, He H

- 1372 Gemcitabine-induced peripheral vascular disease and prolonged response in a patient with metastatic pancreatic adenocarcinoma: A case report

Fabien MB, Elodie P, Anna S, Addeo P, Meher B

- 1379 Epidemic Japanese B encephalitis combined with contactin-associated protein-like 2 antibody-positive autoimmune encephalitis: A case report

Huang P

- 1385 Acute pancreatitis as initial presentation of acute myeloid leukemia-M2 subtype: A case report

Yang WX, An K, Liu GF, Zhou HY, Gao JC

- 1393 Postoperative jaundice related to *UGT1A1* and *ABCB11* gene mutations: A case report and literature review

Jiang JL, Liu X, Pan ZQ, Jiang XL, Shi JH, Chen Y, Yi Y, Zhong WW, Liu KY, He YH

- 1403 Hidrotic ectodermal dysplasia in a Chinese pedigree: A case report

Liao MY, Peng H, Li LN, Yang T, Xiong SY, Ye XY

- 1410 Hepatitis A virus-associated acute acalculous cholecystitis in an adult-onset Still's disease patient: A case report and review of the literature

Chang CH, Wang YY, Jiao Y

- 1419 Transverse myelitis caused by herpes zoster following COVID-19 vaccination: A case report

Cho SY, Jang BH, Seo JW, Kim SW, Lim KJ, Lee HY, Kim DJ

1426 Primary malignant melanoma of the esophagus: A case report

Wang QQ, Li YM, Qin G, Liu F, Xu YY

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Goran Augustin, MD, MSc, PhD, Assistant Professor, Senior Scientist, Surgeon, Department of Surgery, University Hospital Centre Zagreb, Zagreb 10000, Croatia. augustin.goran@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases (WJCC, World J Clin Cases)* is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The *WJCC* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for *WJCC* as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The *WJCC*'s CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Ying-Yi Yuan*; Production Department Director: *Xu Guo*; Editorial Office Director: *Jin-Lei Wang*.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

February 26, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease

Maria Martin-Grau, Daniel Monleon

Specialty type: Medicine, research and experimental

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C, C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Gao P, China; Tan X, China

Received: September 20, 2022

Peer-review started: September 20, 2022

First decision: October 18, 2022

Revised: November 30, 2022

Accepted: February 2, 2023

Article in press: February 2, 2023

Published online: February 26, 2023



Maria Martin-Grau, Daniel Monleon, Department of Pathology, University of Valencia, Valencia 46010, Spain

Corresponding author: Daniel Monleon, PhD, Professor, Department of Pathology, University of Valencia, Avenue Blasco Ibañez, 15, Valencia 46010, Spain. daniel.monleon@uv.es

Abstract

Metabolic-associated fatty liver disease (MAFLD) refers to the build-up of fat in the liver associated with metabolic dysfunction and has been estimated to affect a quarter of the population worldwide. Although metabolism is highly influenced by the effects of sex hormones, studies of sex differences in the incidence and progression of MAFLD are scarce. Metabolomics represents a powerful approach to studying these differences and identifying potential biomarkers and putative mechanisms. First, metabolomics makes it possible to obtain the molecular phenotype of the individual at a given time. Second, metabolomics may be a helpful tool for classifying patients according to the severity of the disease and obtaining diagnostic biomarkers. Some studies demonstrate associations between circulating metabolites and early and established MAFLD, but little is known about how metabolites relate to and encompass sex differences in disease progression and risk management. In this review, we will discuss the epidemiological metabolomic studies for sex differences in the development and progression of MAFLD, the role of metabolic profiles in understanding mechanisms and identifying sex-dependent biomarkers, and how this evidence may help in the future management of the disease.

Key Words: MAFLD; Sex differences; Metabolic profiles; Metabolism

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Metabolic-associated fatty liver disease (MAFLD) refers to the build-up of fat in the liver associated with metabolic dysfunction and has been estimated to affect a quarter of the population worldwide. Metabolomics represents a powerful approach to studying metabolic disease, including MAFLD, and to identify potential biomarkers and putative mechanisms. Some studies demonstrate associations between circulating metabolites and early and established MAFLD, but little is known about how metabolites relate to and encompass sex differences in disease progression and risk management. In this review, we will discuss the role of metabolic profiles in understanding mechanisms and identifying sex-dependent biomarkers, and how this evidence may help in the future management of the disease.

Citation: Martin-Grau M, Monleon D. Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease. *World J Clin Cases* 2023; 11(6): 1236-1244

URL: <https://www.wjgnet.com/2307-8960/full/v11/i6/1236.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v11.i6.1236>

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases that occurs with different stages ranging from steatosis to cirrhosis or hepatocellular carcinoma. In 2020, the classical conception of NAFLD was revised and consequently, a new entity called metabolic-associated fatty liver disease (MAFLD) was defined. Unlike NAFLD, MAFLD does not exclude patients who consume alcohol or those who have other liver diseases. MAFLD prioritizes and values the metabolic involvement of the liver and the consequences of liver metabolism impairment on the progression of the disease[1]. At the clinical level, MAFLD seems more useful for the study of the advanced stages of the disease, since, by focusing on the metabolic dysfunction, MAFLD allows to include a greater number of patients and individuals at risk than the classic definition of NAFLD[2]. However, as expected for recently proposed definitions, the criteria for the use of MAFLD as a clinical entity is not unanimous and NAFLD is still the most used term[3]. Currently, the prevalence of NAFLD and MAFLD is continuously increasing in both adult and child populations due to the epidemics of obesity and type 2 diabetes mellitus. Although MAFLD and NAFLD share a large part of their clinical profile and produce similar long-term outcomes, the actual trend for increase mortality for both of them reflect different situations. Increased liver-related mortality among NAFLD patients seems driven by NAFLD-related liver complications and extra-hepatic diseases such as cardiovascular disease, extra-hepatic cancers, or kidney diseases[4]. MAFLD patients show greater risk for all-cause mortality and an equal risk for cause-specific mortality comparing to NAFLD patients[5].

The prevalence of MAFLD is very high worldwide with numbers rapidly increasing in low- and mid-income countries. In adulthood, the average prevalence of MAFLD worldwide in 2015 was 25%, being higher in South America (31%) and the Middle East (32%)[6]. More recent studies show even higher rates of MAFLD with an estimated prevalence in adults as high as 30%, being even higher in the Middle East and North Africa (approximately 43%) followed by South America and Asia (approximately 33%)[7]. The numbers at a young age are especially worrisome. In childhood, one of the greatest risk factors that contribute to the initiation and development of MAFLD is obesity. In overweight and obese children, the prevalence of MAFLD can reach up to 36%. Nevertheless, the worldwide prevalence of MAFLD among the general pediatric population is 8% with the highest rate in Central America and the Middle East[8,9].

The prevalence of MAFLD seems to differ among men and women even at young ages. The prevalence of MAFLD in the juvenile population is higher in men than in women both before and after puberty[8,10]. In the adult population, the prevalence of MAFLD is also higher in men than in premenopausal women. However, the incidence in post-menopausal women increases markedly suggesting a potential role for sex hormones in the mechanisms of the disease[7,11].

The burden of the disease in the national health systems and the population is increasingly higher. Due to the increase in cases in children, the disease becomes chronic at a younger age. It is estimated that, in the coming decades, the incidence will continue increasing and so will the costs in health systems worldwide[7,9]. We herein review the influence of sex hormones on hepatic and mitochondrial metabolism and how sex hormones contribute to the development of MAFLD. It seems critical to identify new risk and early disease biomarkers, which include relevant biological factors like sex in the risk estimation, for a future better management of the disease. Therefore, we specifically focus on if the sex variable is currently considered when stratifying patients in metabolomics studies and if it is used to search new biomarkers based on metabolomics in the development of MAFLD.


SEX AND LIVER METABOLISM

The liver is an organ with a key role in the homeostasis of human metabolism. Due to the architecture of the hepatic lobules and the arrangement of the portal triad with respect to the hepatic vein, there is a metabolic zonation in the liver, which leads to a liver metabolism not exactly uniform within the hepatic lobule[12]. The liver is an organ with a high metabolic rate and, among other functions, is responsible for regulating lipid and carbohydrate metabolism in the body. Regarding lipid metabolism, circulating lipids enter the hepatocyte and can: (1) Be oxidized for energy, (2) be esterified and form very-low-density lipoprotein (VLDL) particles, and (3) stored and stay in the hepatocyte. In addition, the hepatocyte can synthesize new lipids by de novo lipogenesis (DNL). Regarding carbohydrate metabolism, the liver can store sugars in the form of glycogen or synthesize de novo carbohydrates depending on the needs of the body. Both lipid and carbohydrate metabolism are coupled and highly regulated. When the homeostasis of metabolism is altered, lipids can accumulate pathologically in the organ causing stress and cell damage and sugars can remain circulating in the blood aggravating insulin resistance[13].

Sex hormones are steroid hormones derived from the cholesterol molecule. All sex hormones can bind to receptors in the liver cells. Based on their chemical structure, they are classified into three large groups: estrogens, androgens, and progestogens[14]. The liver is actively involved in the metabolism and interconversion of these sex hormones[15]. Estrogens, the main female sex hormone, are divided into estrone (E1), 17 β -estradiol (E2) and estriol (E3), being E2 the main one. Like any steroid hormone, 95% of estrogens travel through the bloodstream binding to steroid hormone-binding globulin. The remaining 5% circulates freely. Estrogens bind to its receptors, estrogen receptors (ERs), present in the cell nucleus. There are two types, ER α and ER β , which are differentially expressed depending on tissue [16,17]. In addition, there is a third type of receptor called the G-protein-coupled estrogen receptor, which is located on the plasma membrane and is also important in estrogen signaling and cell function [18]. Androgens, the main male sex hormone, belong to a group of sex hormones that includes among others, testosterone, and dihydrotestosterone. These hormones bind to androgen receptors, located in the cell nucleus[14]. Finally, progesterone is a hormone released by the corpus luteum into the ovary. It is mainly responsible for the stimulation of the mammary glands, and the preparation and maintenance of pregnancy. Progesterone can bind to two nuclear progesterone receptors (PR), PR-A and PR-B, expressed primarily in areas of the brain. Other receptors for progesterone located on the plasma membrane have also been described[19]. In women, the ovaries are responsible for producing estrogens, progestogens and androgens, which can be aromatized and converted into estrogen. In men, Leydig cells present in the testicles produce testosterone, which can aromatize and become estrogen[17].

Hepatic metabolism is highly regulated and sex hormones have been shown to contribute significantly to this regulation. Up to 72% of the genes related to liver metabolism can be expressed differentially based on sex[20]. The effects of sex hormones on liver metabolism are summarized in Figure 1. Estrogens are directly related to a protective mechanism against liver fat accumulation by promoting lipolysis and inhibiting DNL. In addition, estrogens contribute to maintaining a hepatic cholesterol balance by promoting lipoprotein synthesis, the secretion of VLDL particles, increasing high-density lipoprotein production and eliminating oxidized low-density lipoprotein. They also improve mitochondrial function, increase free fatty acid (FFA) oxidation, improve glucose tolerance as well as insulin sensitivity and decrease inflammatory processes in the liver[14,17,20,21]. Androgens also have some protective role against the development of hepatic steatosis. They can promote VLDL exocytosis, DNL inhibition, homeostasis of carbohydrate metabolism and mitochondrial beta-oxidation of FFA[14, 20]. The role of progesterone in fat liver metabolism and accumulation seems more diluted. Although this hormone is metabolized in the liver, the impact on woman liver health may be partially detrimental. High levels of progesterone in women are related to the development of insulin resistance and some liver damage[22]. Not only are the mechanisms explaining these effects unclear, but also, more investigations are needed to confirm these observations.

There are certain situations in which the levels of sex hormones decrease both in men and women. This condition is known as hypogonadism and has been related to the development of MAFLD[21]. Menopause or estrogen hypogonadism, physiological conditions in which estrogen levels abruptly decrease, have a notable impact on women. Decreased estrogen levels in women can lead to increased hepatic steatosis by decreasing VLDL secretion and increasing DNL[14,20,23]. Decreased estrogen levels also encompass a decrease in the body's metabolic rate which contributes to weight gain and the development of obesity[16], factors that contribute to the incidence of insulin resistance and an increased risk of developing liver fibrosis[14,20]. Healthy women have higher levels of estrogen than androgens. However, this situation is reversed in polycystic ovary syndrome (PCOS). PCOS is one of the most common endocrinopathies associated with young women that is characterized by high levels of androgens, lack of ovulation and the presence of polycystic ovaries. Hyperandrogenism associated with PCOS doubles the risk of developing MAFLD, and increases the incidence of obesity, insulin resistance and metabolic syndrome, all related to MAFLD, compared to female controls[24-26]. In men, hypogonadism is a syndrome that is defined by decreased testosterone levels. Hypogonadism due to testosterone deficiency has also been shown to increase the risk of developing hepatic steatosis, obesity, and insulin resistance[24,27]. A recent meta-analysis revealed that total serum testosterone was



DOI: 10.12998/wjcc.v11.i6.1236 Copyright ©The Author(s) 2023.

Figure 1 Effects of androgens and estrogens in liver metabolism. (+) means higher concentration and (–) less concentrations of specific sex hormone. (↑) means an increase and (↓) a decrease in a specific hepatic function. DNL: *De novo* lipogenesis.

decreased in men with MAFLD *vs* men without MAFLD[28]. Decreased androgen levels in men leads to an increase in circulating triglycerides[23], a decrease in VLDL secretion, an increase in DNL, insulin resistance, and increased body weight[14,20], all of them related to MAFLD.

MITOCHONDRIAL METABOLISM, THE LIVER, AND SEX HORMONES

Mitochondria represent approximately 20% of the hepatocyte volume[29]. They carry out critical metabolic functions related to lipids, carbohydrates, and amino acids. The conversion of pyruvate to acetyl-CoA and its oxidation occurs through the tricarboxylic acid (TCA) cycle at the mitochondrial matrix. This cycle generates adenosine triphosphate (ATP), nicotinamide adenine dinucleotide, flavin adenine dinucleotide and other important metabolites such as citrate, succinate, malate, and oxaloacetate. Citrate, a precursor molecule of lipogenesis, is synthesized in the mitochondrial matrix and exported to the cytosol for the initiation of DNL. Succinate is transformed into fumarate by the electron transport chain (ETC) for cellular respiration and ATP production. Malate and oxaloacetate may initiate the process of gluconeogenesis for glucose synthesis. In turn, acetyl-CoA can be used for the synthesis of ketone bodies in a process known as ketogenesis. The beta-oxidation of fatty acids, which generates a large amount of acetyl-CoA, also takes place in the mitochondrial matrix. The acetyl-CoA produced during beta-oxidation of fatty acids can also enter the TCA cycle or alternatively initiate ketogenesis[29,30]. On the other hand, the ETC is not perfect and during respiration free radicals can be produced. As a consequence, the mitochondria are the place in the cell where more reactive oxygen species (ROS) are produced. Under physiological conditions, antioxidant systems cope with the accumulation of ROS and decrease the number of toxic molecules. However, under pathological conditions, the accumulation of ROS can affect the integrity of DNA, both mitochondrial and nuclear. In addition, mitochondria are related to the production of S-adenosylmethionine, a methyl group donor molecule. This molecule can modulate gene expression by producing epigenetic changes in DNA. Finally, the mitochondria act as a sensor of cell viability, being related to processes of apoptosis and necrosis[30]. All these events and processes taking place at the mitochondria combined with the predominant role of mitochondria in liver metabolism places this organelle at the center of many mechanistic hypotheses about MAFLD pathogenesis[29].

Mitochondria are also regulated by sex hormones. Estrogens stimulate the expression of mitochondrial proteins encoded in nuclear DNA as ATP synthase-related proteins or ETC proteins. Estrogens offer protection against the degenerative effects of age by increasing antioxidant defenses, increasing ATP levels, decreasing lipoperoxidation, and decreasing levels of ROS. In addition, estrogens co-regulate the processes of mitochondrial fusion and fission, enhancing mitochondrial biogenesis and inhibiting mitophagy and apoptosis. Estrogens also promote mitochondrial DNA transcription and stimulate oxygen consumption[31-33]. Androgens, on the other hand, stimulate mitochondrial biogenesis by increasing mitochondrial content (mitochondrial DNA and mitochondrial proteins), inhibiting mitophagy, maintaining the integrity of ETC and protecting these organelles from the degenerative effects of age[32,34]. The impact of MAFLD in the interaction between sex hormones and mitochondria can be two-fold. First, MAFLD can alter sex hormone levels and consequently decrease the protective effect on the mitochondria (Figure 1). Second, the accumulation of FFA and sugars inside the hepatocyte can impact the metabolic functions in the mitochondrial matrix. The most dramatic consequences include alterations in the cell respiration pattern, with decreased ATP production and an overproduction of ROS. Beta-oxidation can also be hampered with FFA to be consumed by alternative

pathways in peroxisomes (beta-oxidation) or microsomes (omega-oxidation), which in turn can increase ROS and toxic intermediates (dicarboxylic acids) production. All these alterations produce ultra-structural mitochondrial changes at different levels. Different studies report increased permeability of the outer and inner membranes, abnormal mitochondria shapes or deletion of mitochondrial DNA[35, 36]. All these facts suggest that the study of mitochondrial metabolism both in the cell and also by studying mitochondrial metabolism products in available biofluids (such as blood) may help in further investigating fatty liver disease mechanisms. The identification of early mitochondrial dysfunction, combined with other risk factors, like body mass index, sex, and age, may provide the basis for early detection and risk stratification in MAFLD management.

METABOLIC PROFILES TO CHARACTERIZE SEX DIMORPHISM IN MAFLD

Each molecule involved in the chemical reactions that take place in a living organism is called a metabolite. The set of metabolites involved in all the chemical reactions in a living organism is called the metabolome. Omics are a set of analytical sciences that are responsible for the study of a specific biological set. Currently, there are many types of omics, however, the big four omics are genomics, transcriptomics, proteomics, and metabolomics[37,38]. There are mainly two analytical techniques that allow detecting (qualitative analysis) and quantifying (quantitative analysis) metabolites in biological samples. These are Nuclear Magnetic Resonance (NMR) and Mass Spectroscopy (MS)[39,40]. With NMR and MS, the metabolites existing in a biological sample (serum, plasma, urine, faeces, cells, or tissue) at the time of measurement can be determined. Because the metabolome is at the end of the -omics cascade, metabolomics reflects changes that occur at the proteomic, transcriptomic, or genomic level. Consequently, interpretation of metabolite levels and metabolomic profile is highly complex. Subsequently metabolomics is more used for identifying relevant biomarkers and signatures and less used for providing mechanistic hints. Nevertheless, metabolomics can be a helpful tool in the study of diseases in which metabolic dysfunction is at the center of the pathogenesis, such as MAFLD[41,42].

The metabolome is sex-dependent since very early stages of life. In general, biological sex differences can be included into one of 3 groups: (1) Sex dimorphisms, in which some biological trait is only expressed in men or women; (2) Sex differences, in which a biological trait has a range of possibilities but is predominant in one sex with respect the other; and (3) Conditions in which there is no obvious difference between sexes for some biological trait but differences can show up under some conditions like stress, disease or some pharmacological treatments[43,44]. The extension of these three groups to metabolites as biological traits is straightforward. Metabolites, which are different between men and women only in MAFLD patients would fall within the third group and would represent ideal candidates for a stratified MAFLD risk model.

There are sex dimorphisms and sex differences in many metabolic processes of the organism, specifically of the liver, which are intrinsically related to many other differences detailed in the sections above, including sex hormones, and mitochondria function. Most metabolic pathologies, as MAFLD, affect differently men and women, with different risk factors, different disease progression and even difference prevalence under similar conditions[45]. The alteration of sex hormones, due to age or due to some pathological processes, and the development of MAFLD are strongly associated. **Figure 2** shows a simplified summary of these links (**Figure 2**). Although most, if not all, epidemiological studies have information about the sex of the participants, only in the last decades -omics studies have analyzed their data adjusting or stratifying by sex, and many suggested biomarkers are released with unisex models. Our knowledge about the influence of sex and sex hormones in metabolism strongly suggest that these analyses need to be stratified by sex (not just adjusted) for identifying sex-specific biomarkers and building sex-dependent risk models. **Table 1** shows different studies which analyzed the metabolome and the metabolic changes happening in established NAFLD accounting for the metabolic differences between men and women. A recent study suggests that cardiovascular risk in NAFLD patients could be stratified according to levels of Trimethylamine-N-oxide (TMAO), which is a gut microbiota-derived metabolite associated to cardiovascular risk[46]. In another study, women exhibited lower levels of TMAO than men. In addition, obese patients at higher risk of NAFLD also showed higher levels of TMAO. However, the authors did not stratify women by pre- or post-menopause and estrogen influence in these levels and associated risk[47]. In a different research, serum metabolomic profiles were measured in a young cohort at two time-points, at approximately 10 years old (T1) and 16 years old (T2). There were metabolites significantly different between MAFLD and controls at both time points and different between boys and girls. All the metabolites were related to lipid, amino acid, and carbohydrate metabolism[48]. Branched-chain amino acids (BCCA) are critical switches between health and disease[49]. A recent study analyzed these metabolites in obese patients with different NAFLD severity. They concluded that there was a correlation between BCCA levels, sex, and the degree of MAFLD severity. In women, the concentration of BCCAs in plasma was lower than in men. However, the levels of BCCA in women sharply increase with disease progression from control to non-alcoholic steatohepatitis (NASH)-fibrosis, whereas in men a parallel decrease was observed. Interestingly, there was a strong association between circulating BCAA and liver fibrosis only present in women[50].

Table 1 Studies related to “fatty liver disease”, “metabolomics” and “sex”

Ref.	Cohort origin	No. of patients	Sex variable	Platform used	Different metabolites between sexes
Barrea <i>et al</i> [47], 2018	Naples, Italy	137	59 men (43.1%) and 78 women (56.9%)	HPLC-MS	Serum TMAO
Perng <i>et al</i> [48], 2020	Exploring Perinatal Outcomes among Children (EPOCH), USA	395	199 boys (50.7%) and 196 girls (49.3%)	MS	Lipid, amino acid, nucleotide and carbohydrates metabolism pathways
Grzych <i>et al</i> [50], 2020	Antwerp University Hospital (Belgium)	112	53 men (47.3%) and 59 women (52.7%)	MS	Leucine, valine and isoleucine (BCAA)
Ioannou <i>et al</i> [51], 2020	USA	57	51 men (89.5%) and 6 women (10.5%)	LC-MS and NMR	Mainly BCAA, lactate, TMAO, choline and creatinine
McGlinchey <i>et al</i> [52], 2022	UK, France, Germany, Brazil and Italy	627	339 men (54%) and 287 women (45%)	UHPLC coupled to QTOFMS, and GC coupled to QTOFMS	Serum lipids and polar metabolites (lactate, citrate, isoleucine, lysine, alanine, <i>etc.</i>)

BCAA: Branched chain amino acid; GC: Gas chromatography; HPLC-MS: High-performance liquid chromatography – mass spectroscopy; LC-MS: Liquid chromatography – mass spectrometry; MS: Mass spectroscopy; NMR: Nuclear magnetic resonance; QTOFMS: Quadrupole-time-of-flight mass spectrometry; TMAO: Trimethylamine-N-oxide; UHPLC: Ultrahigh-performance liquid chromatography.




Figure 2 The use of metabolomics in the context of metabolic-associated fatty liver disease and sex hormones. Liver metabolism is affected by sex hormone levels. It has been seen that, in metabolic-associated fatty liver disease (MAFLD) disease, there is a decrease in androgens and estrogens which influences liver metabolism. Metabolomics allows the measurement and study of metabolites in a biological sample (liver tissue, blood, urine, faeces, *etc.*). The application of metabolomics to men and women at different stages of the disease would provide great information for the search of biomarkers and the study of MAFLD.

Although liver disease can be diagnosed by noninvasive measurements, the gold standard still remains the liver biopsy. Biopsy-confirmed MAFLD classified by degree of severity in simple steatosis, early NASH, and advanced NASH was used to obtain metabolomic profiles of liver disease progression in another metabolomic study. Although the sample size was low and the power of the study was limited, the authors identify some differences between different degrees of severity which did not correlate with differences between sexes[51]. Finally, a larger study also analyzed serum metabolomics in 627 patients to classify them based on the degree of severity of the disease stratified by sex. The authors identified a set of common metabolic traits associated to liver disease severity regardless of sex and a different set of

metabolites that changed specifically in men or in women. In the fibrosis stage, men presented 5 sex-specific metabolic differences whereas women show 17 sex-specific metabolic differences[52].

CONCLUSION

Metabolism is highly influenced by the effects of sex hormones. Specifically, hepatic metabolism and mitochondrial metabolism change depending on sex hormone levels. Recent studies show that individuals with altered estrogen or androgens levels have higher risk of developing fatty liver disease or progressing to more severe stages than those with normal levels. MAFLD is associated to metabolic alterations in liver and mitochondria. Among these, the identification of early mitochondrial dysfunction, combined with other risk factors, like body mass index, sex, and age, may provide the basis for early detection and risk stratification in MAFLD management. Because the metabolome is at the end of the -omics cascade, metabolomics reflects changes that occur at the proteomic, transcriptomic, or genomic level. Metabolomics is a helpful tool in the study of diseases in which metabolic dysfunction is at the center of the pathogenesis, such as MAFLD. In this review, we briefly explained the role of different metabolic compartments in the development of MAFLD and critically review current state-of-the-art evidence from metabolomic studies on sex dependency of fatty liver disease. Not only are more studies needed to clarify the role of metabolites and their use as biomarkers, but also, it is vital that future research includes the sex variable.

FOOTNOTES

Author contributions: Martin-Grau M and Monleon D contributed to writing and revising; All authors have read and approved the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Spain

ORCID number: Daniel Monleon 0000-0002-4803-1573.

S-Editor: Liu GL

L-Editor: A

P-Editor: Liu GL

REFERENCES

- 1 **Eslam M**, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbaek H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol* 2020; **73**: 202-209 [PMID: 32278004 DOI: 10.1016/j.jhep.2020.03.039]
- 2 **Lin S**, Huang J, Wang M, Kumar R, Liu Y, Liu S, Wu Y, Wang X, Zhu Y. Comparison of MAFLD and NAFLD diagnostic criteria in real world. *Liver Int* 2020; **40**: 2082-2089 [PMID: 32478487 DOI: 10.1111/liv.14548]
- 3 **Fouad Y**, Dufour JF, Zheng MH, Bollipo S, Desalegn H, Grønbaek H, Gish RG. The NAFLD-MAFLD debate: Is there a Consensus-on-Consensus methodology? *Liver Int* 2022; **42**: 742-748 [PMID: 35182007 DOI: 10.1111/liv.15197]
- 4 **Mantovani A**, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. *Metabolism* 2020; **111S**: 154170 [PMID: 32006558 DOI: 10.1016/j.metabol.2020.154170]
- 5 **Huang Q**, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality? *Front Med (Lausanne)* 2021; **8**: 693507 [PMID: 34277667 DOI: 10.3389/fmed.2021.693507]
- 6 **Younossi Z**, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol* 2018; **15**: 11-20 [PMID: 28930295 DOI: 10.1038/nrgastro.2017.109]
- 7 **Henry L**, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. *Aliment Pharmacol Ther* 2022; **56**: 942-956 [PMID: 35880713 DOI: 10.1111/apt.17158]

- 8 **Shaunak M**, Byrne CD, Davis N, Afolabi P, Faust SN, Davies JH. Non-alcoholic fatty liver disease and childhood obesity. *Arch Dis Child* 2021; **106**: 3-8 [PMID: 32409495 DOI: 10.1136/archdischild-2019-318063]
- 9 **Powell EE**, Wong VW, Rinella M. Non-alcoholic fatty liver disease. *Lancet* 2021; **397**: 2212-2224 [PMID: 33894145 DOI: 10.1016/S0140-6736(20)32511-3]
- 10 **Zou ZY**, Zeng J, Ren TY, Huang LJ, Wang MY, Shi YW, Yang RX, Zhang QR, Fan JG. The burden and sexual dimorphism with nonalcoholic fatty liver disease in Asian children: A systematic review and meta-analysis. *Liver Int* 2022; **42**: 1969-1980 [PMID: 34619026 DOI: 10.1111/liv.15080]
- 11 **Balakrishnan M**, Patel P, Dunn-Valadez S, Dao C, Khan V, Ali H, El-Serag L, Hernaez R, Sisson A, Thrift AP, Liu Y, El-Serag HB, Kanwal F. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2021; **19**: 61-71.e15 [PMID: 32360810 DOI: 10.1016/j.cgh.2020.04.067]
- 12 **Trefts E**, Gannon M, Wasserman DH. The liver. *Curr Biol* 2017; **27**: R1147-R1151 [PMID: 29112863 DOI: 10.1016/j.cub.2017.09.019]
- 13 **Ding HR**, Wang JL, Ren HZ, Shi XL. Lipometabolism and Glycometabolism in Liver Diseases. *Biomed Res Int* 2018; **2018**: 1287127 [PMID: 31205932 DOI: 10.1155/2018/1287127]
- 14 **Yang M**, Ma F, Guan M. Role of Steroid Hormones in the Pathogenesis of Nonalcoholic Fatty Liver Disease. *Metabolites* 2021; **11** [PMID: 34067649 DOI: 10.3390/metabo11050320]
- 15 **Rhyu J**, Yu R. Newly discovered endocrine functions of the liver. *World J Hepatol* 2021; **13**: 1611-1628 [PMID: 34904032 DOI: 10.4254/wjh.v13.i11.1611]
- 16 **Chen KL**, Madak-Erdogan Z. Estrogens and female liver health. *Steroids* 2018; **133**: 38-43 [PMID: 29100781 DOI: 10.1016/j.steroids.2017.10.015]
- 17 **Ceccarelli I**, Bioletti L, Peparini S, Solomita E, Ricci C, Casini I, Miceli E, Aloisi AM. Estrogens and phytoestrogens in body functions. *Neurosci Biobehav Rev* 2022; **132**: 648-663 [PMID: 34890602 DOI: 10.1016/j.neubiorev.2021.12.007]
- 18 **Gaudet HM**, Cheng SB, Christensen EM, Filardo EJ. The G-protein coupled estrogen receptor, GPER: The inside and inside-out story. *Mol Cell Endocrinol* 2015; **418** Pt 3: 207-219 [PMID: 26190834 DOI: 10.1016/j.mce.2015.07.016]
- 19 **Sundström-Poromaa I**, Comasco E, Sumner R, Luders E. Progesterone - Friend or foe? *Front Neuroendocrinol* 2020; **59**: 100856 [PMID: 32730861 DOI: 10.1016/j.yfrne.2020.100856]
- 20 **Della Torre S**. Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology. *Cells* 2021; **10** [PMID: 34572151 DOI: 10.3390/cells10092502]
- 21 **Von-Hafe M**, Borges-Canha M, Vale C, Leite AR, Sérgio Neves J, Carvalho D, Leite-Moreira A. Nonalcoholic Fatty Liver Disease and Endocrine Axes-A Scoping Review. *Metabolites* 2022; **12** [PMID: 35448486 DOI: 10.3390/metabo12040298]
- 22 **Xu L**, Yuan Y, Che Z, Tan X, Wu B, Wang C, Xu C, Xiao J. The Hepatoprotective and Hepatotoxic Roles of Sex and Sex-Related Hormones. *Front Immunol* 2022; **13**: 939631 [PMID: 35860276 DOI: 10.3389/fimmu.2022.939631]
- 23 **Kur P**, Kolasa-Wołosiuk A, Misiakiewicz-Has K, Wiszniewska B. Sex Hormone-Dependent Physiology and Diseases of Liver. *Int J Environ Res Public Health* 2020; **17** [PMID: 32290381 DOI: 10.3390/ijerph17082620]
- 24 **Gariani K**, Jornayvaz FR. Pathophysiology of NASH in endocrine diseases. *Endocr Connect* 2021; **10**: R52-R65 [PMID: 33449917 DOI: 10.1530/EC-20-0490]
- 25 **Singep AM**, Stanciu C, Huiban L, Muzica CM, Cuciureanu T, Girleanu I, Chiriac S, Zenovia S, Nastasa R, Sfarti C, Cojocariu C, Trifan A. Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications. *Can J Gastroenterol Hepatol* 2021; **2021**: 6678142 [PMID: 33505943 DOI: 10.1155/2021/6678142]
- 26 **Chen MJ**, Ho HN. Hepatic manifestations of women with polycystic ovary syndrome. *Best Pract Res Clin Obstet Gynaecol* 2016; **37**: 119-128 [PMID: 27107966 DOI: 10.1016/j.bpobgyn.2016.03.003]
- 27 **Hermoso DAM**, Bizerra PFV, Constantin RP, Ishii-Iwamoto EL, Gilglioni EH. Association between metabolic syndrome, hepatic steatosis, and testosterone deficiency: evidences from studies with men and rodents. *Aging Male* 2020; **23**: 1296-1315 [PMID: 32406295 DOI: 10.1080/13685538.2020.1764927]
- 28 **Jaruvongvanich V**, Sanguankeo A, Riangwiwat T, Upala S. Testosterone, Sex Hormone-Binding Globulin and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. *Ann Hepatol* 2017; **16**: 382-394 [PMID: 28425408 DOI: 10.5604/16652681.1235481]
- 29 **Di Ciaula A**, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? *Int J Mol Sci* 2021; **22** [PMID: 34065331 DOI: 10.3390/ijms22105375]
- 30 **Morio B**, Panthu B, Bassot A, Rieusset J. Role of mitochondria in liver metabolic health and diseases. *Cell Calcium* 2021; **94**: 102336 [PMID: 33387847 DOI: 10.1016/j.cecca.2020.102336]
- 31 **Ventura-Clapier R**, Piquereau J, Veksler V, Garnier A. Estrogens, Estrogen Receptors Effects on Cardiac and Skeletal Muscle Mitochondria. *Front Endocrinol (Lausanne)* 2019; **10**: 557 [PMID: 31474941 DOI: 10.3389/fendo.2019.00557]
- 32 **Klinge CM**. Estrogenic control of mitochondrial function. *Redox Biol* 2020; **31**: 101435 [PMID: 32001259 DOI: 10.1016/j.redox.2020.101435]
- 33 **Álvarez-Delgado C**. The role of mitochondria and mitochondrial hormone receptors on the bioenergetic adaptations to lactation. *Mol Cell Endocrinol* 2022; **551**: 111661 [PMID: 35483518 DOI: 10.1016/j.mce.2022.111661]
- 34 **Yin L**, Luo M, Wang R, Ye J, Wang X. Mitochondria in Sex Hormone-Induced Disorder of Energy Metabolism in Males and Females. *Front Endocrinol (Lausanne)* 2021; **12**: 749451 [PMID: 34987473 DOI: 10.3389/fendo.2021.749451]
- 35 **Ferramosca A**, Di Giacomo M, Zara V. Antioxidant dietary approach in treatment of fatty liver: New insights and updates. *World J Gastroenterol* 2017; **23**: 4146-4157 [PMID: 28694655 DOI: 10.3748/wjg.v23.i23.4146]
- 36 **Ramanathan R**, Ali AH, Ibdah JA. Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease. *Int J Mol Sci* 2022; **23** [PMID: 35806284 DOI: 10.3390/ijms23137280]
- 37 **Manzoni C**, Kia DA, Vandrovцова J, Hardy J, Wood NW, Lewis PA, Ferrari R. Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences. *Brief Bioinform* 2018; **19**: 286-302 [PMID: 27881428 DOI: 10.1093/bib/bbw114]
- 38 **Dai X**, Shen L. Advances and Trends in Omics Technology Development. *Front Med (Lausanne)* 2022; **9**: 911861 [PMID: 35806284 DOI: 10.3390/ijms23137280]

- 35860739 DOI: [10.3389/fmed.2022.911861](https://doi.org/10.3389/fmed.2022.911861)]
- 39 **Jacob M**, Lopata AL, Dasouki M, Abdel Rahman AM. Metabolomics toward personalized medicine. *Mass Spectrom Rev* 2019; **38**: 221-238 [PMID: [29073341](https://pubmed.ncbi.nlm.nih.gov/29073341/) DOI: [10.1002/mas.21548](https://doi.org/10.1002/mas.21548)]
 - 40 **Belhaj MR**, Lawler NG, Hoffman NJ. Metabolomics and Lipidomics: Expanding the Molecular Landscape of Exercise Biology. *Metabolites* 2021; **11** [PMID: [33799958](https://pubmed.ncbi.nlm.nih.gov/33799958/) DOI: [10.3390/metabo11030151](https://doi.org/10.3390/metabo11030151)]
 - 41 **Perakakis N**, Stefanakis K, Mantzoros CS. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. *Metabolism* 2020; **111S**: 154320 [PMID: [32712221](https://pubmed.ncbi.nlm.nih.gov/32712221/) DOI: [10.1016/j.metabol.2020.154320](https://doi.org/10.1016/j.metabol.2020.154320)]
 - 42 **Alharthi J**, Eslam M. Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update. *J Clin Transl Hepatol* 2022; **10**: 134-139 [PMID: [35233382](https://pubmed.ncbi.nlm.nih.gov/35233382/) DOI: [10.14218/JCTH.2021.00248](https://doi.org/10.14218/JCTH.2021.00248)]
 - 43 **Miller VM**. Why are sex and gender important to basic physiology and translational and individualized medicine? *Am J Physiol Heart Circ Physiol* 2014; **306**: H781-H788 [PMID: [24414073](https://pubmed.ncbi.nlm.nih.gov/24414073/) DOI: [10.1152/ajpheart.00994.2013](https://doi.org/10.1152/ajpheart.00994.2013)]
 - 44 **Mauvais-Jarvis F**, Arnold AP, Reue K. A Guide for the Design of Pre-clinical Studies on Sex Differences in Metabolism. *Cell Metab* 2017; **25**: 1216-1230 [PMID: [28591630](https://pubmed.ncbi.nlm.nih.gov/28591630/) DOI: [10.1016/j.cmet.2017.04.033](https://doi.org/10.1016/j.cmet.2017.04.033)]
 - 45 **Lefebvre P**, Staels B. Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease. *Nat Rev Endocrinol* 2021; **17**: 662-670 [PMID: [34417588](https://pubmed.ncbi.nlm.nih.gov/34417588/) DOI: [10.1038/s41574-021-00538-6](https://doi.org/10.1038/s41574-021-00538-6)]
 - 46 **Tang WH**, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N Engl J Med* 2013; **368**: 1575-1584 [PMID: [23614584](https://pubmed.ncbi.nlm.nih.gov/23614584/) DOI: [10.1056/NEJMoa1109400](https://doi.org/10.1056/NEJMoa1109400)]
 - 47 **Barrea L**, Annunziata G, Muscogiuri G, Di Somma C, Laudisio D, Maisto M, de Alteriis G, Tenore GC, Colao A, Savastano S. Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome. *Nutrients* 2018; **10** [PMID: [30551613](https://pubmed.ncbi.nlm.nih.gov/30551613/) DOI: [10.3390/nu10121971](https://doi.org/10.3390/nu10121971)]
 - 48 **Perng W**, Francis EC, Smith HA, Carey J, Wang D, Kechris KM, Dabelea D. Sex-Specific Metabolite Biomarkers of NAFLD in Youth: A Prospective Study in the EPOCH Cohort. *J Clin Endocrinol Metab* 2020; **105**: e3437-e3450 [PMID: [32687159](https://pubmed.ncbi.nlm.nih.gov/32687159/) DOI: [10.1210/clinem/dgaa467](https://doi.org/10.1210/clinem/dgaa467)]
 - 49 **Zhang ZY**, Monleon D, Verhamme P, Staessen JA. Branched-Chain Amino Acids as Critical Switches in Health and Disease. *Hypertension* 2018; **72**: 1012-1022 [PMID: [30354823](https://pubmed.ncbi.nlm.nih.gov/30354823/) DOI: [10.1161/HYPERTENSIONAHA.118.10919](https://doi.org/10.1161/HYPERTENSIONAHA.118.10919)]
 - 50 **Grzych G**, Vonghia L, Bout MA, Weyler J, Verrijken A, Dirinck E, Chevalier Curt MJ, Van Gaal L, Paumelle R, Francque S, Tailleux A, Haas JT, Staels B. Plasma BCAA Changes in Patients With NAFLD Are Sex Dependent. *J Clin Endocrinol Metab* 2020; **105** [PMID: [32271385](https://pubmed.ncbi.nlm.nih.gov/32271385/) DOI: [10.1210/clinem/dgaa175](https://doi.org/10.1210/clinem/dgaa175)]
 - 51 **Ioannou GN**, Nagana Gowda GA, Djukovic D, Raftery D. Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach. *Metabolites* 2020; **10** [PMID: [32344559](https://pubmed.ncbi.nlm.nih.gov/32344559/) DOI: [10.3390/metabo10040168](https://doi.org/10.3390/metabo10040168)]
 - 52 **McGlinchey AJ**, Govaere O, Geng D, Ratziu V, Allison M, Bousier J, Petta S, de Oliveira C, Bugianesi E, Schattenberg JM, Daly AK, Hyötyläinen T, Anstee QM, Orešič M. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. *JHEP Rep* 2022; **4**: 100477 [PMID: [35434590](https://pubmed.ncbi.nlm.nih.gov/35434590/) DOI: [10.1016/j.jhepr.2022.100477](https://doi.org/10.1016/j.jhepr.2022.100477)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

